{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:21:46Z","timestamp":1788837706594,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.109992","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T14:41:26Z","timestamp":1779028886000},"page":"109992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Biphenyl sulfonylurea Analogs as novel antiangiogenic agents: A repositioning and molecular modelling strategy"],"prefix":"10.1016","volume":"179","author":[{"given":"Dharti H.","family":"Modh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mit","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhoomika M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Deokar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinayak S.","family":"Walhekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vithal M.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109992_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.772305","article-title":"Novel pathways for targeting tumor angiogenesis in metastatic breast Cancer","volume":"11","author":"Harry","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109992_bb0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.31557\/apjcb.2024.9.1.97-103","article-title":"Angiogenesis in breast Cancer: a review","volume":"9","author":"Gamde","year":"2024","journal-title":"Asian Pac. J. Cancer Biol."},{"key":"10.1016\/j.bioorg.2026.109992_bb0015","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.7150\/jca.44313","article-title":"Angiogenesis in breast Cancer progression, diagnosis, and treatment","volume":"11","author":"Madu","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109992_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.med.57.121304.131306","article-title":"Angiogenesis","volume":"57","author":"Folkman","year":"2006","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bioorg.2026.109992_bb0025","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3390\/cells3020304","article-title":"Mechanisms of activation of receptor tyrosine kinases: monomers or dimers","volume":"3","author":"Maruyama","year":"2014","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2026.109992_bb0030","series-title":"Small Molecules in Oncology","first-page":"145","article-title":"Sorafenib: targeting multiple tyrosine kinases in Cancer","volume":"23","author":"Hasskarl","year":"2014"},{"key":"10.1016\/j.bioorg.2026.109992_bb0035","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109992_bb0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2010.02.012","article-title":"Pazopanib: clinical development of a potent anti-angiogenic drug","volume":"77","author":"Schutz","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bioorg.2026.109992_bb0045","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1080\/09553002.2020.1730012","article-title":"Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage","volume":"97","author":"Mehta","year":"2021","journal-title":"Int. J. Radiat. Biol."},{"key":"10.1016\/j.bioorg.2026.109992_bb0050","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1586\/14737140.2015.1042369","article-title":"Linifanib: current status and future potential in cancer therapy","volume":"15","author":"Aversa","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.bioorg.2026.109992_bb0055","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s43042-019-0035-0","article-title":"Exploring receptor tyrosine kinases-inhibitors in Cancer treatments","volume":"20","author":"Metibemu","year":"2019","journal-title":"Egypt. J. Med. Hum. Genet."},{"key":"10.1016\/j.bioorg.2026.109992_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911937","article-title":"Caspase 3 and cleaved caspase 3 expression in Tumorogenesis and its correlations with prognosis in head and neck Cancer: a systematic review and Meta-analysis","volume":"23","author":"Silva","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109992_bb0065","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/14656566.2017.1309024","article-title":"Sorafenib for the treatment of breast cancer","volume":"18","author":"Bronte","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.109992_bb0070","doi-asserted-by":"crossref","first-page":"331","DOI":"10.5306\/wjco.v7.i4.331","article-title":"Sorafenib in breast cancer treatment: a systematic review and overview of clinical trials","volume":"7","author":"Zafrakas","year":"2016","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109992_bb0075","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1517\/13543784.2012.652304","article-title":"Pazopanib for the treatment of breast cancer","volume":"21","author":"Amiri-Kordestani","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bioorg.2026.109992_bb0080","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2174\/1389557523666230509123036","article-title":"Anticancer drug discovery by structure-based repositioning approach","volume":"1","author":"Modh","year":"2024","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109992_bb0085","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1016\/j.bmc.2015.04.071","article-title":"Discovery of biphenyl-aryl ureas as novel VEGFR-2 inhibitors. Part 4: exploration of diverse hinge-binding fragments","volume":"23","author":"Su","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109992_bb0090","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1021\/ml500394m","article-title":"Distinct binding mode of multikinase inhibitor Lenvatinib revealed by biochemical characterization","volume":"6","author":"Okamoto","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109992_bb0095","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1080\/07391102.2020.1747543","article-title":"An in-silico approach: identification of PPAR-\u03b3 agonists from seaweeds for the management of Alzheimer's disease","volume":"39","author":"Kotha","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2026.109992_bb0100","doi-asserted-by":"crossref","first-page":"10278","DOI":"10.1080\/07391102.2021.1942212","article-title":"Carbazole-based semicarbazones and hydrazones as multifunctional anti-Alzheimer agents","volume":"40","author":"Patel","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2026.109992_bb0105","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1080\/07391102.2021.1872417","article-title":"Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: binding site analysis of type II, \u2018DFG-out\u2019 inhibitors","volume":"40","author":"Modi","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2026.109992_bb0110","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1021\/acschemneuro.0c00448","article-title":"Further studies on Triazinoindoles as potential novel multitarget-directed anti-Alzheimer\u2019s agents","volume":"11","author":"Patel","year":"2020","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.bioorg.2026.109992_bb0115","first-page":"1150","article-title":"Evaluation of in vitro and in vivo anticancer potential of two 5-acetamido chalcones against breast cancer","volume":"16","author":"Wankhede","year":"2017","journal-title":"EXCLI J."},{"key":"10.1016\/j.bioorg.2026.109992_bb0120","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40360-018-0284-4","article-title":"In vitro wound healing of tumor cells: inhibition of cell migration by selected cytotoxic alkaloids","volume":"20","author":"Wang","year":"2019","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.bioorg.2026.109992_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112851","article-title":"Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): reversal of TGF-\u03b2 induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma","volume":"207","author":"Modi","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109992_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/antiox11020231","article-title":"Oxidant\/antioxidant status is impaired in sepsis and is related to anti-apoptotic, inflammatory, and innate immunity alterations","volume":"11","author":"Miliaraki","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.bioorg.2026.109992_bb0135","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000542875","article-title":"Chick Chorioallantoic membrane as an in vivo model for the study of angiogenesis and Lymphangiogenesis","volume":"62","author":"Wan","year":"2024","journal-title":"J. Vasc. Res."},{"key":"10.1016\/j.bioorg.2026.109992_bb0140","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.yrtph.2019.02.008","article-title":"Developing OECD test guidelines for regulatory testing of nanomaterials to ensure mutual acceptance of test data","volume":"104","author":"Rasmussen","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109992_bb0145","article-title":"Synthesis and computational studies on novel thiazine-thiazole hybrid analogues as dual \u03b1-amylase and \u03b1-glucosidase inhibitors for combating diabetes mellitus","volume":"120","author":"Rehman","year":"2025","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.109992_bb0150","article-title":"New thiazine derivatives with dual potential for lipoxygenase inhibition and hemolytic activity: synthesis, characterization and molecular docking studies","volume":"120","author":"Khan","year":"2025","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.109992_bb0155","first-page":"1","article-title":"Design, synthesis and computational approaches of highly potent thiazole-based isoxazole targeting thymidine phosphorylase and urease inhibitors","author":"Khan","year":"2025","journal-title":"J. Comput. Biophys. Chem."},{"key":"10.1016\/j.bioorg.2026.109992_bb0160","article-title":"Discovery and optimization of a novel series of pyrazole-linked oxadiazole conjugates as \u03b1-amylase inhibitors: in-silico DFT, ADMET-prediction, toxicological assessment and molecular docking insight","volume":"1351","author":"Sarfraz","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.109992_bb0165","doi-asserted-by":"crossref","DOI":"10.1515\/pac-2025-0649","article-title":"Identification of bis-thiazole linked oxazine Schiff bases: synthesis, in-vitro biological evaluation and computational insights toward potent urease and thymidine phosphorylase inhibitors","author":"Khan","year":"2026","journal-title":"Pure Appl. Chem."},{"key":"10.1016\/j.bioorg.2026.109992_bb0170","doi-asserted-by":"crossref","first-page":"8883","DOI":"10.1007\/s00210-025-04879-1","article-title":"Design, synthesis and biological profiling of bis-thiazole linked Schiff bases as effective enzyme inhibitors for targeting urease and thymidine phosphorylase proteins","volume":"399","author":"Khan","year":"2026","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"12","key":"10.1016\/j.bioorg.2026.109992_bb0175","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1515\/pac-2025-0459","article-title":"Novel hybrid indazole-based 2, 4-dihydro-3 H-1, 2, 4-triazole-3-thione derivatives: design, synthesis, spectroscopic characterization, SAR, molecular docking, pharmacokinetics and toxicological activities","volume":"97","author":"Arshad","year":"2025","journal-title":"Pure Appl. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826005286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826005286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:27:04Z","timestamp":1780993624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826005286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"alternative-id":["S0045206826005286"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109992","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biphenyl sulfonylurea Analogs as novel antiangiogenic agents: A repositioning and molecular modelling strategy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109992","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109992"}}